HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...
Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with...
Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC
WUXI, China, Sept. 2, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regulatory clearance from China's National Medical...
Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
FDA IND Clearance for CBL-0201WR—Caliway has cleared its Investigational New Drug application for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide. U.S. IRB Approval for Pivotal Phase 3 Trial SUPREME-01 (CBL-0301)—The...
SuperX Announces Progress on Share Repurchase Program, Initiates New Buyback Plan to Reinforce Confidence in Long-Term Growth Value
SINGAPORE, Aug. 7, 2026 /PRNewswire/ -- SuperX AI Technology Limited (Nasdaq: SUPX, the "Company" or "SuperX"), a provider of AI infrastructure solutions, today announced an update on the progress of its share repurchase program and the adoption of...
Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature...
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
The coalition, titled the Indonesian Coalition for Financial Health, was officially launched on June 4 at the Asia Grassroots Forum 2026 and initiated by Amartha together with partners. Fully supported by Her Majesty Queen Maxima of the Netherlands...
Robo.ai Subsidiary Neurovia AI Announces NeuroStream™ Architecture at ISNR 2026 and Initiates Commercial Proof of Concept Phase
ABU DHABI, UAE, May 22, 2026 /PRNewswire/ -- Robo.ai announced that its subsidiary, Neurovia AI, disclosed its recent technological and commercial developments following the conclusion of the 2026 International Exhibition for National Security and...
Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC...
Robo.ai Initiates Revenue Recognition for Intelligent Data Business and Advances Tens of Thousands of Hours of Capacity Cooperation Across the Middle East and Asia
DUBAI, UAE, March 24, 2026 /PRNewswire/ -- Robo.ai Inc. (NASDAQ: AIIO) (the "Company" or "Robo.ai") today announced the capacity expansion plan for its intelligent data business segment. Following the delivery of its initial batch of real-world...